(S)-2-(1,1,6-trimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one | 1278585-23-1

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: (S)-2-(1,1,6-trimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one
• 英文别名: (2S)-2-[(1,1,6-trimethyl-2,3-dihydroinden-5-yl)oxymethyl]-2,3-dihydro-[1,3]oxazolo[3,2-a]pyrimidin-7-one
• CAS: 1278585-23-1
• 化学式: C₁₉H₂₂N₂O₃
• 分子量: 326.395
• InChiKey: OGHIUFHEWRVWNT-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  51.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF<br/>[FR] DIHYDRO-BENZOCYCLOALKYL-OXYMÉTHYL-OXAZOLOPYRIMIDINONES SUBSTITUÉES, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：SANOFI AVENTIS

  公开号：WO2011034830A1

  公开（公告）日：2011-03-24

  The present invention relates to a series of substituted dihydro benzocycloalkyl-oxymethyl oxazolopyrimidinones of formula (I) as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, cognition deficit disorders, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

  本发明涉及一系列取代二氢苯并环烷氧甲基噁唑嘧啶酮化合物，其化学式为（I），如本文所定义。本发明还涉及制备这些化合物的方法，包括新颖的中间体。本发明的化合物是代谢型谷氨酸受体（mGluR）的调节剂，特别是mGluR2受体。因此，本发明的化合物可作为药物剂，特别是在治疗和/或预防各种中枢神经系统疾病（CNS）方面有用，包括但不限于急性和慢性神经退行性疾病、精神病、认知缺陷疾病、癫痫、焦虑、抑郁、偏头痛、疼痛、睡眠障碍和呕吐。
• SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF
  申请人：SHER Rosy

  公开号：US20120184566A1

  公开（公告）日：2012-07-19

  The present invention relates to a series of substituted dihydro benzocycloalkyl-oxymethyl oxazolopyrimidinones of formula (I): Wherein n, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, cognition deficit disorders, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

  本发明涉及一系列取代二氢苯并环烷氧甲基噁唑嘧啶酮化合物，其化学式为(I)：其中n，R1，R2，R3，R4，R5和R6如本文所定义。本发明还涉及制备这些化合物的方法，包括新型中间体。本发明的化合物是代谢型谷氨酸受体（mGluR）的调节剂，特别是mGluR2受体。因此，本发明的化合物在制药领域中有用，特别是在治疗和/或预防各种中枢神经系统疾病（CNS），包括但不限于急性和慢性神经退行性病变，精神病，认知缺陷障碍，惊厥，焦虑，抑郁，偏头痛，疼痛，睡眠障碍和呕吐等方面。
• US9051331B2
  申请人：——

  公开号：US9051331B2

  公开（公告）日：2015-06-09